Cargando…

Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

OBJECTIVE: To evaluate the efficacy and safety of subcutaneous peginterferon beta-1a over 2 years in patients with relapsing–remitting multiple sclerosis in the ADVANCE study. METHODS: Patients were randomized to placebo or 125 µg peginterferon beta-1a every 2 or 4 weeks. For Year 2 (Y2), patients o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kieseier, Bernd C, Arnold, Douglas L, Balcer, Laura J, Boyko, Alexey A, Pelletier, Jean, Liu, Shifang, Zhu, Ying, Seddighzadeh, Ali, Hung, Serena, Deykin, Aaron, Sheikh, Sarah I, Calabresi, Peter A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2015
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4512519/ https://www.ncbi.nlm.nih.gov/pubmed/25432952 http://dx.doi.org/10.1177/1352458514557986

Ejemplares similares

Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis
por: Arnold, Douglas L, et al.
Publicado: (2014)

Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence of disease activity in relapsing-remitting multiple sclerosis: 2-year results from the ADVANCE randomized controlled trial
por: Arnold, Douglas L., et al.
Publicado: (2017)

Population‐Based Pharmacokinetic and Exposure‐Efficacy Analyses of Peginterferon Beta‐1a in Patients With Relapsing Multiple Sclerosis
por: Hu, Xiao, et al.
Publicado: (2017)

Subgroup and sensitivity analyses of annualized relapse rate over 2 years in the ADVANCE trial of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis
por: Newsome, Scott D., et al.
Publicado: (2016)

Improvement in relapse recovery with peginterferon beta-1a in patients with multiple sclerosis
por: Scott, Thomas F, et al.
Publicado: (2016)

Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsingremitting multiple sclerosis in the randomized ADVANCE study
por: Hu, Xiao, et al.
Publicado: (2015)

Analysis of peginterferon β-1a exposure and Gd-enhanced lesion or T2 lesion response in relapsing-remitting multiple sclerosis patients
por: Hang, Yaming, et al.
Publicado: (2016)

Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN
por: Newsome, Scott D., et al.
Publicado: (2018)

Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-Ia in Subjects with Normal or Impaired Renal Function
por: Hu, Xiao, et al.
Publicado: (2015)

Temporal profile of serum neurofilament light in multiple sclerosis: Implications for patient monitoring
por: Calabresi, Peter A, et al.
Publicado: (2020)

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
por: Hu, Xiao, et al.
Publicado: (2016)

Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study
por: Arnold, Douglas L., et al.
Publicado: (2017)

Measuring treatment response to advance precision medicine for multiple sclerosis
por: Calabresi, Peter A., et al.
Publicado: (2021)

Retinal pathology in multiple sclerosis: insight into the mechanisms of neuronal pathology
por: Calabresi, Peter A., et al.
Publicado: (2010)

An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex(® )prefilled syringe in multiple sclerosis subjects
por: Phillips, J Theodore, et al.
Publicado: (2011)

Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks
por: Hendin, Barry, et al.
Publicado: (2018)

An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists
por: Kolb-Mäurer, Annette, et al.
Publicado: (2019)

Peginterferon beta-1a was associated with high adherence and satisfaction in patients with multiple sclerosis in a German real-world study
por: Menge, Til, et al.
Publicado: (2021)

Peginterferon β-1a every 2 weeks increased achievement of no evidence of disease activity over 4 years in the ADVANCE and ATTAIN studies in patients with relapsing–remitting multiple sclerosis
por: Arnold, Douglas L., et al.
Publicado: (2018)

Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis
por: Chang, Ih, et al.
Publicado: (2022)

New immunopathologic insights into multiple sclerosis
por: Hemmer, Bernhard, et al.
Publicado: (2003)

Pregnancy Outcomes Following Maternal and Paternal Exposure to Teriflunomide During Treatment for Relapsing–Remitting Multiple Sclerosis
por: Kieseier, Bernd C., et al.
Publicado: (2014)

Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C
por: Pouresmaeeli, Mahdiyar, et al.
Publicado: (2015)

Erythropoietin Ameliorates Rat Experimental Autoimmune Neuritis by Inducing Transforming Growth Factor-Beta in Macrophages
por: Mausberg, Anne K., et al.
Publicado: (2011)

Global Peginterferon Beta-1a Tolerability Management Best Practices: A Nurse-Focused Delphi Approach
por: White, Sarah, et al.
Publicado: (2021)

Immunomodulatory potential of anti-IFN-beta antibodies on monocyte-derived macrophages
por: Sominanda, Ajith, et al.
Publicado: (2023)

Elasomeran/peginterferon: Autoimmune hepatitis: case report
Publicado: (2022)

Retinal Damage in Amyotrophic Lateral Sclerosis: Underlying Mechanisms
por: Soldatov, Vladislav O, et al.
Publicado: (2021)

How patients with multiple sclerosis acquire disability
por: Lublin, Fred D, et al.
Publicado: (2022)

A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
por: Xiao, Nan, et al.
Publicado: (2010)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Identification of targets and new developments in the treatment of multiple sclerosis – focus on cladribine
por: Warnke, Clemens, et al.
Publicado: (2010)

Review of teriflunomide and its potential in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2009)

Defining the clinical course of multiple sclerosis: The 2013 revisions
por: Lublin, Fred D., et al.
Publicado: (2014)

Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C
por: Kuo, Ming-Te, et al.
Publicado: (2014)

Peginterferon based therapy for chronic hepatitis C in the elderly patients
por: Bold, Adriana, et al.
Publicado: (2013)

Bioequivalence of intramuscular and subcutaneous peginterferon beta-1a: results of a phase I, open-label crossover study in healthy volunteers
por: Zhao, Yuan, et al.
Publicado: (2021)

Matching comparisons of therapeutic efficacy suggest better clinical outcomes for patients treated with peginterferon beta-1a than with glatiramer acetate
por: Scott, Thomas F., et al.
Publicado: (2021)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study
por: Silva, Giovanni Faria, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_kts9gdg4oerp5jcs2r6lt4qace